Heart Failure with Preserved Ejection Fraction (HFpEF) — Clues to the Identification of Undiagnosed Patients

Prof. Mark Kearney, Executive Dean of the Faculty of Medicine and Health, University of Leeds

Prof. Kearney is the British Heart Foundation Professor of Cardiovascular and Diabetes Research and a clinical consultant cardiologist with an interest in the mechanisms underlying diabetes related heart disease and the natural history and new treatments for patients with heart failure. His research group includes members with a wide range of skills addressing the link between diabetes and cardiovascular disease. Within ten years over 500 million people will suffer from type 2 diabetes which we now know is a disease of the large and small blood vessels.

Mark Kearney’s team is working on the link between changes in insulin and IGF-1 signalling in the blood vessel wall and diabetes with the aim of designing new ways of treating the devastating cardiovascular complications of type 2 diabetes. Mark is currently on the research committee of Diabetes UK having served on the project and fellowship committees of the British Heart Foundation. Mark is passionate about training tomorrow’s leaders in cardiovascular research.

Dr. Elias Ketiar MD, DM MRCP, Sr. Director of Medical Therapeutic Area Strategy, AES

Dr. Ketiar is a Senior Medical Director working in the CMO Team developing new therapeutic strategies and supporting clinical training in AES PPD.

He has extensive experience in general medicine and cardiometabolic diseases and is a Member of the Royal College of Physicians (London), UK.

He has experience in academic research and is involved in pioneering research into genetic causes of congenital heart disease. This culminated with a Medical Doctorate with St. George’s University of London.

He has experience in healthcare systems globally. He has always been interested and involved in medical education and clinical trials. He delivers training regularly on the topic of cardiometabolic diseases and holistic general medicine. Elias applies his practical clinical knowledge and innovates to generate solutions in enhancing patient pathway design resulting in successful trial recruitment, particularly in complicated therapeutic areas.